RxDoctor Payments Data

Emily Bell

Nurse Practitioner · Syracuse, NYNPI 1194201913

Payments from drug & device makers

$467in general payments, 2019–2025

Across 11 payments — averaging $42.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125
  • E.r. Squibb & Sons, L.L.C.$105
  • Neurocrine Biosciences, Inc.$94
  • Otsuka America Pharmaceutical, Inc.$70
  • AbbVie$28
  • Collegium Pharmaceutical, Inc.$18
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$467100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$467 in reported general payments places this provider in the 80th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$40,373
Medicare patients
98
Services billed
559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$27,507
EliquisApixaban70$26,558
ArexvyRsvpref3 Antigen/As01e/Pf58$18,142
SantylCollagenase Clostridium Hist.20$12,079
XareltoRivaroxaban15$7,545
LinzessLinaclotide14$7,050
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,782
MyrbetriqMirabegron18$5,522
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc21$1,898
Sucralfate11$1,090
Insulin Lispro Kwikpen U-100Insulin Lispro14$1,024
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$885
Mirtazapine28$847
Albuterol Sulfate HfaAlbuterol Sulfate22$751
Atorvastatin Calcium90$689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$13$7,54515 claims
AbbVieLinzess$28$7,05014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →